Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1548-1563

  Brison, Elodie ^a   Jacomy, Hélène ^a   Desforges, Marc ^a   Talbot, Pierre J ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; GLIAL TRANSPORTER 1 PROTEIN; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; MEMANTINE; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORONAVIRUS; CORONAVIRUS INFECTION; CYTOSKELETON; EMBRYO; EXCITOTOXICITY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MORTALITY; MOUSE; NERVE CELL PLASTICITY; NEUROFILAMENT; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CORONAVIRUS INFECTIONS; CORONAVIRUS OC43, HUMAN; FEMALE; GLUTAMIC ACID; HUMANS; MEMANTINE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS REPLICATION;

EID: 84892624364     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02972-13     Document Type: Article

References (87)

1. Buchmeier MJ, Lane TE. 1999. Viral-induced neurodegenerative disease. Curr. Opin. Microbiol. 2:398-402. http://dx.doi.org/10.1016/S1369-5274(99)80070-8.
2. Talbot PJ, Jacomy H, Desforges M. 2008. Pathogenesis of human coronaviruses other than severe acute respiratory syndrome coronavirus, p 313-324. In Perlman S, Gallagher T, Snilder EJ (ed), The nidoviruses. ASM Press, Washington, DC.
3. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, Mc-Caustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399. http://dx.doi.org/10.1126/science.1085952.
4. Riski H, Hovi T. 1980. Coronavirus infections of man associated with diseases other than the common cold. J. Med. Virol. 6:259-265. http://dx .doi.org/10.1002/jmv.1890060309.
5. Forgie S, Marrie TJ. 2009. Healthcare-associated atypical pneumonia. Semin. Resp. Crit. Care 30:67-85. http://dx.doi.org/10.1055/s-0028-1119811.
6. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. 2004. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics 113:e73-e76.
7. Bonavia A, Arbour N, Yong VW, Talbot PJ. 1997. Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43. J. Virol. 71:800-806.
8. Arbour N, Côté G, Lachance C, Tardieu M, Cashman NR, Talbot PJ. 1999. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J. Virol. 73:3338-3350.
9. Arbour N, Ekandé S, Côté G, Lachance C, Chagnon F, Tardieu M, Cashman NR, Talbot PJ. 1999. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. J. Virol. 73:3326-3337.
10. Edwards JA, Denis F, Talbot PJ. 2000. Activation of glial cells by human coronavirus OC43 infection. J. Neuroimmunol. 108:73-81. http://dx.doi .org/10.1016/S0165-5728(00)00266-6.
11. Jacomy H, Talbot PJ. 2003. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology 315:20-33. http://dx.doi.org/10 .1016/S0042-6822(03)00323-4.
12. Arbour N, Day R, Newcombe J, Talbot PJ. 2000. Neuroinvasion by human respiratory coronaviruses. J. Virol. 74:8913-8921. http://dx.doi .org/10.1128/JVI.74.19.8913-8921.2000.
13. Olney J. 1978. Neurotoxicity of excitatory amino acids, p 95-121. In McGeer EG, Olney JW, McGeer PL (ed), Kainic acid as a tool in neurobiology. Raven Press, New York, NY.
14. Mark LP, Prost RW, Ulmer JL, Smith MM, Daniels DL, Strottmann JM, Brown WD, Hacein-Bey L. 2001. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. AJNR Am. J. Neuroradiol. 22:1813-1824.
15. Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J. 2000. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm. Genome 11:1107-1110. http://dx.doi.org/10.1007/s003350010190.
16. Kvamme E, Nissen-Meyer LS, Roberg BA, Torgner IA. 2008. Novel form of phosphate activated glutaminase in cultured astrocytes and human neuroblastoma cells, PAG in brain pathology and localization in the mitochondria. Neurochem. Res. 33:1341-1345. http://dx.doi.org/10.1007/s11064-008-9589-9.
17. Shijie J, Takeuchi H, Yawata I, Harada Y, Sonobe Y, Doi Y, Liang J, Hua L, Yasuoka S, Zhou Y, Noda M, Kawanokuchi J, Mizuno T, Suzumura A. 2009. Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J. Exp. Med. 217: 87-92. http://dx.doi.org/10.1620/tjem.217.87.
18. Huang Y, Zhao L, Jia B, Wu L, Li Y, Curthoys N, Zheng JC. 2011. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J. Neurosci. 31:15195-15204. http://dx.doi.org/10.1523/JNEUROSCI.2051-11.2011.
19. Sattler R, Tymianski M. 2000. Molecular mechanisms of calciumdependent excitotoxicity. J. Mol. Med. (Berl.) 78:3-13. http://dx.doi.org/10.1007/s001090000077.
20. Tilleux S, Hermans E. 2007. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J. Neurosci. Res. 85:2059-2070. http://dx.doi.org/10.1002/jnr.21325.
21. Norenberg MD. 1979. Distribution of glutamine synthetase in the rat central nervous system. J. Histochem. Cytochem. 27:756-762. http://dx .doi.org/10.1177/27.3.39099.
22. Norenberg MD, Martinez-Hernandez A. 1979. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res. 161:303-310. http://dx.doi.org/10.1016/0006-8993(79)90071-4.
23. Albrecht J, Sidoryk-Wegrzynowicz M, Zielinska M, Aschner M. 2010. Roles of glutamine in neurotransmission. Neuron Glia Biol. 6:263-276. http://dx.doi.org/10.1017/S1740925X11000093.
24. Arundine M, Tymianski M. 2003. Molecular mechanisms of calciumdependent neurodegeneration in excitotoxicity. Cell Calcium 34:325-337. http://dx.doi.org/10.1016/S0143-4160(03)00141-6.
25. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J. 2000. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355:1949-1954. http://dx.doi.org/10.1016/S0140-6736(00)02326-6.
26. Kemp JA, McKernan RM. 2002.NMDAreceptor pathways as drug targets. Nat. Neurosci. 5(Suppl):1039-1042. http://dx.doi.org/10.1038/nn936.
27. Parsons CG, Stoffler A, Danysz W. 2007. Memantine: a NMDA receptor antagonistthatimprovesmemorybyrestorationofhomeostasisintheglutamatergic system-toolittle activation is bad, toomuchis even worse. Neuropharmacology 53:699-723. http://dx.doi.org/10.1016/j.neuropharm.2007.07.013.
28. Lipton SA. 2004. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1:101-110. http://dx.doi.org/10.1602/neurorx.1.1.101.
29. Dong XX, Wang Y, Qin ZH. 2009. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30:379-387. http://dx.doi.org/10.1038/aps.2009.24.
30. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. 2013. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 698:6-18. http://dx.doi.org/10.1016/j.ejphar.2012.10 .032.
31. Wilkinson D. 2012. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int. J. Geriatr. Psychiatry 27:769-776. http://dx.doi.org/10.1002/gps.2788.
32. Starck M, Albrecht H, Pollmann W, Dieterich M, Straube A. 2010. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J. Neurol. 257: 322-327. http://dx.doi.org/10.1007/s00415-009-5309-x.
33. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladstrom A, Jones R. 2010. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9:969-977. http://dx.doi.org/10.1016/S1474-4422(10)70194-0.
34. Anitha M, Nandhu MS, Anju TR, Jes P, Paulose CS. 2011. Targeting glutamate mediated excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist-memantine. Med. Hypotheses 76:138-140. http://dx.doi.org/10.1016/j.mehy.2010.09.003.
35. Blakely PK, Kleinschmidt-DeMasters BK, Tyler KL, Irani DN. 2009. Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection. J. Neuropathol. Exp. Neurol. 68:1061-1072. http://dx.doi.org/10.1097/NEN.0b013e3181b8ba14.
36. Cisneros IE, Ghorpade A. 2012. HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS. Curr. HIV Res. 10:392-406. http://dx.doi.org/10.2174/157016212802138832.
37. Fotheringham J, Williams EL, Akhyani N, Jacobson S. 2008. Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes. J. Neuroimmune Pharmacol. 3:105-116. http://dx.doi.org/10.1007/s11481-007-9084-0.
38. Szymocha R, Akaoka H, Dutuit M, Malcus C, Didier-Bazes M, Belin MF, Giraudon P. 2000. Human T-cell lymphotropic virus type 1-infected T lymphocytes impair catabolism and uptake of glutamate by astrocytes via Tax-1 and tumor necrosis factor alpha. J. Virol. 74:6433-6441. http://dx.doi.org/10.1128/JVI.74.14.6433-6441.2000.
39. Billaud JN, Ly C, Phillips TR, de la Torre JC. 2000. Borna disease virus persistence causes inhibition of glutamate uptake by feline primary cortical astrocytes. J. Virol. 74:10438-10446. http://dx.doi.org/10.1128/JVI.74 .22.10438-10446.2000.
40. Darman J, Backovic S, Dike S, Maragakis NJ, Krishnan C, Rothstein JD, Irani DN, Kerr DA. 2004. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. J. Neurosci. 24:7566-7575. http://dx.doi.org/10.1523/JNEUROSCI.2002-04.2004.
41. St-Jean JR, Desforges M, Talbot PJ. 2006. Genetic evolution of human coronavirus OC43 in neural cell culture. Adv. Exp. Med. Biol. 581:499-502. http://dx.doi.org/10.1007/978-0-387-33012-9_88.
42. Brison E, Jacomy H, Desforges M, Talbot PJ. 2011. Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. J. Virol. 85:12464-12473. http://dx.doi.org/10.1128/JVI.05576-11.
43. St-Jean JR, Desforges M, Almazan F, Jacomy H, Enjuanes L, Talbot PJ. 2006. Recovery of a neurovirulent human coronavirus OC43 from an infectious cDNA clone. J. Virol. 80:3670-3674. http://dx.doi.org/10.1128/JVI.80.7.3670-3674.2006.
44. Lambert F, Jacomy H, Marceau G, Talbot PJ. 2008. Titration of human coronaviruses using an immunoperoxidase assay. Methods Mol. Biol. 454: 93-102. http://dx.doi.org/10.1007/978-1-59745-181-9_8.
45. Jacomy H, St-Jean JR, Brison E, Marceau G, Desforges M, Talbot PJ. 2010. Mutations in the spike glycoprotein of human coronavirus OC43 modulate disease in BALB/c mice from encephalitis to flaccid paralysis and demyelination. J. Neurovirol. 16:279-293. http://dx.doi.org/10.3109/13550284.2010.497806.
46. Power C, Moench T, Peeling J, Kong PA, Langelier T. 1997. Feline immunodeficiency virus causes increased glutamate levels and neuronal loss in brain. Neuroscience 77:1175-1185. http://dx.doi.org/10 .1016/S0306-4522(96)00531-3.
47. Gupta S, Knight AG, Knapp PE, Hauser KF, Keller JN, Bruce-Keller AJ. 2010. HIV-Tat elicits microglial glutamate release: role ofNAPDHoxidase and the cystine-glutamate antiporter. Neurosci. Lett. 485:233-236. http://dx.doi.org/10.1016/j.neulet.2010.09.019.
48. Chen CJ, Ou YC, Chang CY, Pan HC, Liao SL, Chen SY, Raung SL, Lai CY. 2012. Glutamate released by Japanese encephalitis virus-infected microglia involves TNF-alpha signaling and contributes to neuronal death. Glia 60:487-501. http://dx.doi.org/10.1002/glia.22282.
49. Desforges M, Favreau DJ, Brison E, Desjardins J, Messen-Pinard M, Jacomy H, Talbot PJ. 2013. Human coronavirus: respiratory pathogens revisited as infectious neuroinvasive, neurotropic, and neurovirulent agents, p 93-121. In Singh SK, Ruzek D (ed), Neuroviral infections: RNA viruses and retroviruses. CRC Press LLC, New York, NY.
50. Kvamme E, Roberg B, Torgner IA. 2000. Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain. Neurochem. Res. 25:1407-1419. http://dx.doi.org/10.1023/A:1007668801570.
51. Hogstad S, Svenneby G, Torgner IA, Kvamme E, Hertz L, Schousboe A. 1988. Glutaminase in neurons and astrocytes cultured from mouse brain: kinetic properties and effects of phosphate, glutamate, and ammonia. Neurochem. Res. 13:383-388.
52. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A. 2006. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 281:21362-21368. http://dx .doi.org/10.1074/jbc.M600504200.
53. Danbolt NC. 2001. Glutamate uptake. Prog. Neurobiol. 65:1-105. http://dx.doi.org/10.1016/S0301-0082(00)00067-8.
54. Anderson CM, Swanson RA. 2000. Astrocyte glutamate transport: review of properties,regulation,andphysiologicalfunctions.Glia32:1-14.http://dx.do i.org/10.1002/1098-1136(200010)32:1<1::AID-GLIA10>;3.0.CO;2-W.
55. Wang Z, Pekarskaya O, Bencheikh M, Chao W, Gelbard HA, Ghorpade A, Rothstein JD, Volsky DJ. 2003. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 312:60-73. http://dx.doi .org/10.1016/S0042-6822(03)00181-8.
56. Carmen J, Rothstein JD, Kerr DA. 2009. Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis. Brain Res. 1263:143-154. http://dx .doi.org/10.1016/j.brainres.2009.01.040.
57. Okada K, Yamashita U, Tsuji S. 2005. Modulation of Na(+)-dependent glutamate transporter of murine astrocytes by inflammatory mediators. J. UOEH 27:161-170.
58. Prow NA, Irani DN. 2008. The inflammatory cytokine, interleukin-1 beta, mediates loss of astroglial glutamate transport and drives excitotoxic motor neuron injury in the spinal cord during acute viral encephalomyelitis. J. Neurochem. 105: 1276-1286. http://dx.doi.org/10.1111/j.1471-4159.2008.05230.x.
59. Huang TL, O'Banion MK. 1998. Interleukin-1 beta and tumor necrosis factor-alpha suppress dexamethasone induction of glutamine synthetase in primary mouse astrocytes. J. Neurochem. 71:1436-1442.
60. Zou J, Wang YX, Dou FF, Lu HZ, Ma ZW, Lu PH, Xu XM. 2010. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int. 56:577-584. http://dx.doi.org/10.1016/j.neuint.2009.12.021.
61. Takeda K, Muramatsu M, Chikuma T, Kato T. 2009. Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain. J. Mol. Neurosci. 39:380-390. http://dx.doi .org/10.1007/s12031-009-9224-5.
62. Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB. 2009. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and antiinflammation by preventing microglial activation. Neuropsychopharmacology 34:2344-2357. http://dx.doi.org/10.1038/npp.2009.64.
63. Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. 2000. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 7:153-159. http://dx.doi.org/10.1159/000026433.
64. Liao SL, Chen CJ. 2001. Differential effects of cytokines and redox potential on glutamate uptake in rat cortical glial cultures. Neurosci. Lett. 299:113-116. http://dx.doi.org/10.1016/S0304-3940(01)01499-9.
65. Ackerley S, Grierson AJ, Brownlees J, Thornhill P, Anderton BH, Leigh PN, Shaw CE, Miller CCJ. 2000. Glutamate slows axonal transport of neurofilaments in transfected neurons. J. Cell Biol. 150:165-175. http://dx .doi.org/10.1083/jcb.150.1.165.
66. Miller CCJ, Ackerley S, Brownlees J, Grierson AJ, Jacobsen NJO, Thornhill P. 2002. Axonal transport of neurofilaments in normal and disease states. Cell. Mol. Life Sci. 59:323-330. http://dx.doi.org/10.1007/s00018-002-8425-7.
67. Shea TB, Chan WK, Kushkuley J, Lee S. 2009. Organizational dynamics, functions, and pathobiological dysfunctions of neurofilaments. Results Probl. Cell Differ. 48:29-45. http://dx.doi.org/10.1007/400_2009_8.
68. Schirmer L, Antel JP, Bruck W, Stadelmann C. 2011. Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis. Brain Pathol. 21:428-440. http://dx.doi.org/10.1111/j.1750-3639.2010.00466.x.
69. Tsunoda I, Kuang LQ, Libbey JE, Fujinami RS. 2003. Axonal injury heralds virus-induced demyelination. Am. J. Pathol. 162:1259-1269. http://dx.doi.org/10.1016/S0002-9440(10)63922-3.
70. Perrot R, Berges R, Bocquet A, Eyer J. 2008. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol. Neurobiol. 38:27-65. http://dx.doi.org/10.1007/s12035-008-8033-0.
71. Lipton SA. 2007. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and Snitrosylation. Curr. Drug Targets 8:621-632. http://dx.doi.org/10.2174/138945007780618472.
72. Cady SD, Wang J, Wu Y, DeGrado WF, Hong M. 2011. Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined byNMRspectroscopy. J. Am. Chem. Soc. 133:4274-4284. http://dx.doi.org/10.1021/ja102581n.
73. Ickes DE, Venetta TM, Phonphok Y, Rosenthal KS. 1990. Tromantadine inhibits a late step in herpes simplex virus type 1 replication and syncytium formation. Antiviral Res. 14:75-85. http://dx.doi.org/10 .1016/0166-3542(90)90045-9.
74. Tanner JA, Zheng BJ, Zhou J, Watt RM, Jiang JQ, Wong KL, Lin YP, Lu LY, He ML, Kung HF, Kesel AJ, Huang JD. 2005. The adamantanederived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem. Biol. 12:303-311. http://dx.doi.org/10 .1016/j.chembiol.2005.01.006.
75. Bukrinskaya AG, Vorkunova NK, Narmanbetova RA. 1980. Rimantadine hydrochloride blocks the second step of influenza virus uncoating. Arch. Virol. 66:275-282. http://dx.doi.org/10.1007/BF01314742.
76. Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA. 2002. Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J. Virol. 76:1391-1399. http://dx.doi.org/10.1128/JVI.76.3.1391-1399.2002.
77. Rosenthal KS, Sokol MS, Ingram RL, Subramanian R, Fort RC. 1982. Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob. Agents Chemother. 22:1031-1036. http://dx.doi .org/10.1128/AAC.22.6.1031.
78. Tselis A. 2011. Evidence for viral etiology of multiple sclerosis. Semin. Neurol. 31:307-316. http://dx.doi.org/10.1055/s-0031-1287656.
79. Grant WB, Campbell A, Itzhaki RF, Savory J. 2002. The significance of environmental factors in the etiology of Alzheimer's disease. J. Alzheimer's Dis. 4:179-189.
80. Tisch S, Brew BJ. 2010. HIV, HAART, and Parkinson's disease: coincidence or pathogenetic link? Mov. Disord 25:2257-2258. http://dx.doi .org/10.1002/mds.23277.
81. Ison MG. 2013. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir. Viruses 7(Suppl 1):7-13. http://dx .doi.org/10.1111/irv.12046.
82. Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. 2013. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 87:6551-6559. http://dx.doi.org/10.1128/JVI.00087-13.
83. Page C, Goicochea L, Matthews K, Zhang Y, Klover P, Holtzman MJ, Hennighausen L, Frieman M. 2012. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J. Virol. 86:13334-13349. http://dx.doi.org/10.1128/JVI.01689-12.
84. Noçon AL, Ip JP, Terry R, Lim SL, Getts DR, Muller M, Hofer MJ, King NJ, Campbell IL. 30 October 2013. The bacteriostatic protein lipocalin 2 is induced in the central nervous system with West Nile virus encephalitis. J. Virol. [Epub ahead of print.]. http://dx.doi.org/10 .1128/JVI.02094-13.
85. Li XF, Deng YQ, Yang HQ, Zhao H, Jiang T, Yu XD, Li SH, Ye Q, Zhu SY, Wang HJ, Zhang Y, Ma J, Yu YX, Liu ZY, Li YH, Qin ED, Shi PY, Qin CF. 2013. A chimeric dengue virus vaccine using Japanese encephalitis vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice or nonhuman primates. J. Virol. 87: 13694-13705. http://dx.doi.org/10.1128/JVI.00931-13.
86. Mott KR, Zandian M, Allen SJ, Ghiasi H. 2013. Role of interleukin-2 and herpes simplex virus 1 in central nervous system demyelination in mice. J. Virol. 87:12102-12109. http://dx.doi.org/10.1128/JVI.02241-13.
87. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, Borchelt D, Shaw G. 2009. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J. Neurochem. 111:1182-1191. http://dx.doi.org/10.1111/j.1471-4159.2009.06386.x.